MorphoSys has been granted a patent for antibodies targeting human IL-17C, potentially beneficial for treating inflammatory disorders like atopic dermatitis and psoriasis. The method involves administering specific antibody fragments with defined amino acid sequences to subjects suffering from such conditions. GlobalData’s report on MorphoSys gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MorphoSys, Personalized cancer vaccines was a key innovation area identified from patents. MorphoSys's grant share as of May 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies for treating inflammatory disorders like atopic dermatitis or psoriasis
A recently granted patent (Publication Number: US11987621B2) discloses a method for treating inflammatory disorders by administering specific antibodies or antibody fragments. The method involves utilizing antibodies with defined amino acid sequences targeting human IL-17C, cynomolgus IL-17C, and mouse IL-17C. These antibodies can be human, humanized, or chimeric in nature and may include sequences outlined in SEQ ID NO: 17, SEQ ID NO: 16, SEQ ID NO: 30, and SEQ ID NO: 29. The patent emphasizes the use of isolated or recombinant antibodies in the treatment process.
Furthermore, the patent extends the treatment method by incorporating these antibodies into pharmaceutical compositions along with a pharmaceutically acceptable carrier or excipient. This expanded method provides a comprehensive approach to treating inflammatory disorders by administering the specified antibodies or antibody fragments. The patent also includes a specific embodiment where the antibodies contain sequences from SEQ ID NO: 17, SEQ ID NO: 16, SEQ ID NO: 30, and SEQ ID NO: 29. Overall, the patent highlights a novel therapeutic approach for managing inflammatory disorders through the targeted use of antibodies with defined amino acid sequences.
To know more about GlobalData’s detailed insights on MorphoSys, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
